OrbiMed Invests US$551 Million In Asian Healthcare

The leading healthcare investment firm will use the US$551 million raised to support growth-stage product- and services-oriented companies in China and India.

AsianScientist (Sep. 13, 2017) – OrbiMed, a leading investment firm focused on the healthcare sector, raised approximately US$551 million in capital commitments at the closing of its third Asia-focused private equity fund, OrbiMed Asia Partners III, LP.

Consistent with its predecessor funds, Asia Partners III will invest broadly across the Asian healthcare industry, with a focus on growth-stage product- and services-oriented companies in China and India. The Fund will target investments from US$10 million to US$75 million per company across 15 to 20 opportunities.

Where appropriate, Asia Partners III may co-invest with OrbiMed’s global team, enabling substantially larger investments and leveraging the full financial and strategic resources of more than 100 OrbiMed team members as well as a US$14 billion global investment platform.

“This new, larger fund reflects our enthusiasm for the investment opportunities in China and India, which have healthcare market growth rates far superior to most developed countries,” said Mr. Carter Neild, an OrbiMed General Partner.

“With over half of the world’s patient population, the demand for quality healthcare in Asia still greatly exceeds supply,” said Dr. Jonathan Wang, a Senior Managing Director at OrbiMed. “China’s healthcare market is not only growing rapidly, but also becoming a leading center of innovation, and is increasingly integrated with the rest of the world, especially the US”

“With India still spending less than five percent of its GDP on healthcare and boasting the fastest growth rate of all major economies, we see compelling opportunities for investments across healthcare services, pharmaceuticals, and diagnostics,” said Senior Managing Director Dr. Sunny Sharma, who leads OrbiMed’s team in India.

“OrbiMed now has over US$2 billion invested in Asian healthcare companies, positioning our team as a strong partner for entrepreneurs, institutions and companies seeking to shape the future of Asia’s healthcare markets,” said Dr. David Wang, Senior Managing Director at OrbiMed.


———

Source: OrbiMed; Photo: Shutterstock.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.

Asian Scientist Magazine is an award-winning science and technology magazine that highlights R&D news stories from Asia to a global audience. The magazine is published by Singapore-headquartered Wildtype Media Group.

Related Stories from Asian Scientist